AVNR expects to release topline data no later than end of 3Q09 and plans to submit a complete response to the FDA approvable letter during 1H10. <a href="http://seekingalpha.com/article/136728-fda-clinical-trial-calendars-nine-cash-plus-catalyst-trades" rel="nofollow" target="_blank">http://seekingalpha.com/article/136728-fda-clinical-trial-calendars-nine-cash-plus-catalyst-trades</a>